UBS Group
MIST icon

UBS Group’s Milestone Pharmaceuticals MIST Stock Holding History

UBS Group’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$589K Buy
494,908
+3,040
+0.6% +$5.32K ﹤0.01% 5968
2025
Q4 		$994K Buy
491,868
+94,334
+24% +$203K ﹤0.01% 5582
2025
Q3 		$795K Buy
397,534
+74,886
+23% +$132K ﹤0.01% 5743
2025
Q2 		$626K Buy
322,648
+211,125
+189% +$282K ﹤0.01% 5835
2025
Q1 		$89.2K Buy
111,523
+22,017
+25% +$43.8K ﹤0.01% 7131
2024
Q4 		$211K Buy
+89,506
New +$154K ﹤0.01% 6416
2024
Q2 		– Sell
-2,618
Closed -$4.69K – 9880
2024
Q1 		$4.69K Buy
+2,618
New +$4.25K ﹤0.01% 7604
2023
Q4 		– Sell
-1,693
Closed -$5.25K – 9675
2023
Q3 		$5.25K Sell
1,693
-1,644
-49% -$5.11K ﹤0.01% 7384
2023
Q2 		$9.51K Buy
3,337
+565
+20% +$2.13K ﹤0.01% 7174
2023
Q1 		$10.9K Sell
2,772
-2,413
-47% -$8.82K ﹤0.01% 7541
2022
Q4 		$20.5K Buy
5,185
+1,865
+56% +$9.82K ﹤0.01% 7626
2022
Q3 		$31K Buy
3,320
+2,304
+227% +$17.5K ﹤0.01% 6836
2022
Q2 		$6K Buy
+1,016
New +$6.24K ﹤0.01% 8696
2022
Q1 		– Sell
-1,031
Closed -$7K – 10643
2021
Q4 		$7K Buy
+1,031
New +$6.17K ﹤0.01% 9155
2021
Q3 		– Sell
-483
Closed -$3K – 9861
2021
Q2 		$3K Sell
483
-13,016
-96% -$73.8K ﹤0.01% 8819
2021
Q1 		$78K Sell
13,499
-1,147
-8% -$8.39K ﹤0.01% 6154
2020
Q4 		$98K Sell
14,646
-1,914
-12% -$12.8K ﹤0.01% 5700
2020
Q3 		$121K Buy
16,560
+3,061
+23% +$21.9K ﹤0.01% 5079
2020
Q2 		$51K Hold
13,499
– – ﹤0.01% 5838
2020
Q1 		$25K Buy
+13,499
New +$234K ﹤0.01% 6350

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

UBS Group's MIST Position: Q1 2026 in Review

UBS Group increased its Milestone Pharmaceuticals (MIST) stake by 0.62% in Q1 2026, buying an estimated $5.32K and bringing the position to 494,908 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #5968.

UBS Group first reported a position in MIST in Q1 2020 and has held it in 20 quarters since. The position peaked at $994K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • UBS Group held 494,908 shares of Milestone Pharmaceuticals worth $589K as of Q1 2026.
  • UBS Group bought 3,040 Milestone Pharmaceuticals shares in Q1 2026, an estimated $5.32K.
  • Milestone Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5968 holding.
  • UBS Group first reported a position in Milestone Pharmaceuticals in Q1 2020 and has held it in 20 quarters since.
  • UBS Group's Milestone Pharmaceuticals position peaked at $994K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.